Co-infection of hepatitis E virus and *Plasmodium falciparum* malaria: A genuine risk in sub-Saharan Africa

Syeda Sahra1,3*, Abdullah Jahangir1, Qasim Zafar Iqbal1, Neville Mobarakai1, Allison Glaser1 and Ahmad Jahangir2

**Abstract**

**Background:** There is a high prevalence of malaria and viral hepatitis in South Africa. Co-infection with *Plasmodium* malaria (leading to cerebral malaria) and hepatitis E virus (HEV) is a rare phenomenon.

**Case presentation:** A 33-year-old African American male with no past medical history developed altered mental status on his return from Ivory Coast. His blood tests were significant for renal and liver failure and a high *Plasmodium* parasite burden of 33% on the blood smear. Interestingly, he also had a positive result for hepatitis E IgM. The patient was effectively treated with aggressive hydration and intravenous (IV) artesunate.

**Conclusion:** Our report is the first to our knowledge in the cerebral malaria literature on a patient with hepatitis E co-infection. This exciting case emphasizes the importance of considering all kinds of endemic infectious diseases when evaluating sick returning travelers presenting to the emergency department.

**Keywords:** COVID-19, Cerebral malaria, Hepatitis E virus, HEV, *Plasmodium falciparum*

---

**Introduction**

*Plasmodium* malaria, a mosquito-borne parasitic disease, has been known to humankind since early times. It presents mainly as high-grade fevers, chills, nausea, gastrointestinal symptoms, and anemia. Its high morbidity and mortality are significant health concerns for third world countries even in the current times of advanced treatment and prophylactic options.

Cerebral malaria is one of the deadliest manifestations of *Plasmodium falciparum* infection. Cerebral malaria presents mainly as a neurological sequela secondary to microvascular inflammation from sequestered blood cells, interaction between adhesive proteins and endothelial surfaces, generation of cytokines, and disruption of the blood-brain barrier [1, 2]. Altered mental status is further compounded by accompanying hypoglycemia and electrolyte abnormalities from multiorgan failure.

The prevalence and severity of cerebral malaria are higher in children with life-long neurological complications [3]. Pediatric age group presentation encompasses mainly coma and seizure due to cerebral edema [4]. A study by Carter et al. suggests that cerebral malaria may be responsible for most acquired language disorders [5]. A similar inverse association between cerebral malaria and childhood cognition disorders was established by Boivin et al. [6].

In adults, multiorgan failure usually accompanies the state of altered mental status and coma. Furthermore, neurological deficits are generally long lasting in adults. The treatment of choice for cerebral malaria is
intravenous artesunate, including the pediatric and preg-
nant subgroups [7].

Sub-Saharan Africa is the hub of several infections due
to the low socioeconomic status, lack of hygiene and
sanitation measures, and inadequate health resources.
Hence, both the incidence and prevalence of malaria,
human immunodeficiency virus (HIV), and hepatitis are
exceedingly high in this region, accounting for high
regional morbidity and mortality. Recent studies have
been done to document and understand the co-infec-
tion trends of hepatitis B, hepatitis C, and HIV in the
Ivory Coast [8]. Interestingly, there is a high incidence
of malaria and hepatitis E virus (HEV) infection in the
sub-Saharan population [9]. HEV, spreading through the
oral-fecal route, is known to resolve with symptomatic
management in most cases except in pregnant females
and individuals with hepatic insufficiency. Unfortunately,
the clinical course can escalate quickly to fulminant liver
failure if there is a co-infection with a malarial parasite.
On literature review, rare cases of co-infection with Plas-
modium and HEV have been reported with an abysmal
prognosis. For interest and awareness, we report an unus-
ual case of a co-infection of hepatitis E in a patient who
developed cerebral malaria from Plasmodium falciparum
infection [10].

Case presentation
A 33-year-old African American man with no past medi-
cal history was evaluated in the emergency room (ER)
3 weeks after returning from Ivory Coast. He was born
in Ivory Coast and came to the USA as a toddler. Since
then, he had been visiting Abidjan, Ivory Coast, every
few years to see family. Recently, he spent 1 uneventful
month in Abidjan and returned to the USA. He denied
any history of malaria in the past. He did not take any
anti-malarial prophylaxis during the recent visit. He
confessed to smoking a few tobacco cigarettes daily but
deny any illicit drug abuse. He developed a fever after
7 days. The fever was high grade (103 °F) in intensity and
intermittent, with each episode lasting several hours. The
patient took multiple tablets of over-the-counter Tylenol
and Motrin for the fever at home without any significant
improvement.

The patient had visited the ER twice in the last week
for a similar complaint of low-grade fevers. Thrombo-
cytopenia and transaminitis were seen on blood testing.
However, given the COVID-19 pandemic, recent interna-
tional travel, and blood testing results bearing similarity
to COVID-19, he was promptly tested for COVID-19. He
was discharged home after the COVID-19 polymerase
chain reaction (PCR) test result was negative. The fevers
persisted at home for the next 3 days, nonetheless. Two
days before the presentation, he developed chills, nausea,
and vomiting. The vomiting was initially bilious and later
became dark-colored. The patient’s family noticed that
his mental status had gradually worsened over the past
week, and they decided to bring him to the ER again.

On this visit to the ER, he had an initial temperature
of 101.4 °F, blood pressure of 122/78 mmHg, respiratory
rate of 18 breaths per minute, and oxygen saturation of
98%. Physical examination revealed scleral icterus. The
patient was oriented only to himself with a Glasgow
coma scale (GCS) score of 13 out of 15. The physical
examination did not reveal any hepatosplenomegaly, flap-
ing tremors, or focal neurological deficits.

The initial blood testing was significant for hypoglyce-
mia, pancytopenia (microcytic anemia and thrombocyto-
penia), elevated lactate level, and transaminitis (AST 75
U/l, ALT 36 U/l, bilirubin 15.2 mg/dl, alkaline phosphate
124 U/l) (Tables 1 and 2). The COVID-19 PCR was nega-
tive again.

This time the medical team consulted the Infectious
Diseases service, which recommended obtaining an
immediate peripheral blood smear and acute hepatitis
panel. A peripheral blood smear showed intraerythro-
cytic parasites consistent with Plasmodium falciparum
with a high degree of parasitemia (33%). A lumbar punc-
ture was recommended to rule out cerebral malaria as the
patient was confused. The blood alcohol, acetaminophen,
and salicylate levels were normal. Hepatitis E IgM was
positive, and the rest of the acute hepatitis panel was neg-
ative (Table 3). There was no evidence of retinopathy on
fundoscopic examination. A diagnostic lumber puncture
was performed to rule out cerebral infection. The initial
cerebrospinal fluid (CSF) studies were unremarkable
for any elevated cell count, glucose, or proteins. CSF PCR
studies for E. coli, H. influenzae, Listeria monocytogenes,
Neisseria meningitidis, Streptococcus agalactiae, Strep-
tococcus pneumoniae, sytomegalovirus (CMV), Crypto-
coccus neoforms, herpes simplex virus (HSV-1, HSV-2),
human herpesvirus 6 enterovirus, parechovirus and
varicella zoster virus (VZV) came out negative (Tables 4
and 5). The head CT scan checked for any bleeding, mass
effect, or midline shift (Fig. 1).

Given the high degree of parasitemia and concern
about cerebral malaria, we consulted the regional
Center for Disease Control and Prevention (CDC). The
patient was started on intravenous artesunate (2.4 mg/
kg at 0 h, 12 h, and 24 h). A dramatic improvement was
seen in his blood work and mental status from hospital
day 3. He was fully alert, awake, and oriented to him-
self, time, and place by hospital day 5. Parasitemia was
also entirely resolved by hospital day 5 (0.02%). The
liver enzymes trended down, and the platelet count was
back to normal (Tables 1 and 2). Three negative blood
smears were obtained, and the patient was discharged
home on Coartem (20 mg/120 mg tablets, four tablets as the initial dose, four tablets again after 8 h, and then four tablets twice daily for the following 2 days) with instructions to be closely monitored by the primary care physician. The medicine team followed the patient on telehealth, and he reported doing well and performing his daily activities without any restrictions.

**Table 1** Hematology and comprehensive metabolic panel studies throughout hospitalization and discharge

| Hematology and comprehensive metabolic panel studies | Day 1 | Day 2 am | Day 2 Pm | Day 3 | Day 4 | Day 6 (discharge) | Ten days after discharge |
|-----------------------------------------------------|-------|----------|----------|-------|-------|-------------------|--------------------------|
| Hemoglobin g/dl                                      | 14    | 11.5     | 10       | 8.6   | 8.1   | 7.4               | 8.2                      |
| WBC count k/ul                                       | 7.75  | 9.2      | 10.7     | 12.8  | 12.4  | 16.3              | 8.9                      |
| Platelet count u/l                                   | 36    | 94       | 76       | 91    | 158   | 306               | 541                      |
| Lactate mmol/l                                       | 8.4   | 2.6      |          |       |       |                  |                          |
| AST U/l                                              | 75    | 116      | 229      | 284   | 193   |                  | 50                       |
| ALT U/l                                              | 36    | 48       | 45       | 91    | 156   |                  | 95                       |
| Alkaline phosphate U/l                               | 124   | 116      | 83       | 104   | 157   |                  |                          |
| Albumin g/d/l                                        | 3.6   | 2.8      | 2.6      | 2.5   | 2.6   |                  | 4.2                      |
| Gamma-glutamyl transferase U/l                       | 45    |          |          |       |       |                  |                          |
| Bilirubin total mg/dl                                | 15.2  | 18.4     | 21.6     | 22.5  | 7.9   |                  | 3.2                      |
| Parasitemia %age                                      | 33    | 31.4     | One negative smear | 0.02% | 0.02% |                  |                          |
| BLN mg/dl                                            | 34    | 28       | 26       | 26    | 14    | 17                |                          |
| Creatinine mg/dl                                     | 1.4   | 1.4      | 1.6      | 1.8   | 1.7   | < 0.5             |                          |

**Table 2** Hemolysis panel

| Ferritin ng/ml                                      | 6853  |
| Ceruloplasmin mg/dl                                 | 44    |
| Transferrin mg/dl                                   | 161   |
| Lactate dehydrogenase U/l                           | 1102  |
| Haptoglobin mg/dl                                   | < 20  |

**Table 3** Immunology panel

| Cryptococcal antigen                                 | Negative |
| West Nile virus by PCR                               | Negative |
| Leptospiriosis antibodies                            | Negative |
| Hepatitis A IgM                                      | No      |
| Hepatitis A IgG                                      | Reactive |
| Hepatitis E Ab IgM                                   | Reactive |
| Hepatitis C virus cut-off index                      | 0.04    |
| Hepatitis E IgG                                      | Negative |
| Hep B surface antigen                                | Negative |

**Table 4** CSF studies

| Color                                      | Xanthochromia |
|-------------------------------------------|---------------|
| Glucose mg/dl                             | 62            |
| Protein mg/dl                             | 40            |
| RBC count                                 | 2             |
| Total nucleated cell count                | 2             |
| VDRL titer                                | Nonreactive   |
| LDH, CSF (u/l)                            | 30            |

**Table 5** CSF PCR studies

| West Nile IgM                               | Negative |
| West Nile IgG                               | Negative |
| West Nile virus by PCR                      | Not detected |
| CSF cultures                               | No growth |
| HSV ½ PCR                                  | Negative |
| E. coli K1                                  | Negative |
| Streptococcus agalactiae                   | Negative |
| Streptococcus pneumoniae                   | Negative |
| Cytomegalovirus                            | Negative |
| Human herpes virus 6                       | Negative |
| Human parechovirus                         | Negative |
| Cryptococcus neoformans/gattii             | Negative |
| Lyme PCR, result                           | Negative |
| Haemophilus influenzae                     | Negative |
| Listeria monocytogenes                     | Negative |
| Neisseria meningitidis                     | Negative |
| Human parechovirus                         | Negative |
| Plasmodium, CSF PCR                        | Positive |
outpatient blood testing after discharge from the hospital (Table 1).

**Discussion**

Malaria has a high mortality rate, particularly in the African pediatric population, claiming approximately half a million lives each year [11]. Ninety-two percent of global malarial cases were reported in the World Health Organization (WHO) African Region alone in 2017. Fatal complications, including cerebral malaria, acute respiratory distress syndrome (ARDS), and renal failure, can arise. Severe malaria was attributed to approximately one-tenth of the hospital mortalities in a hospital study done in Abidjan [12].

Apart from mortality, cerebral malaria is a major risk factor for long-term neurological sequelae, including but not limited to epilepsy [13]. Fundoscopy has been employed more frequently recently to evaluate cerebral circulation in patients suspected to have cerebral malaria. We can see patchy retinal whitening and vasculature color changes, pointing toward cerebral microvasculature. The anemia in patients with malaria can be prolonged, though, and artemunate can be a contributing factor.

Our case is unusual as the patient had a co-infection with HEV along with malaria. The transaminitis and his return from Africa triggered the testing for an acute hepatitis panel on the Infectious Diseases team's recommendation. The rest of the hepatitis panel was negative. The patient reported no gastrointestinal symptoms, which is one of the common manifestations of HEV. IgM for hepatitis E was positive, which indicated an acute infection. IgM is positive after the incubation period for HEV is completed, which can range from 2 to 6 weeks. This is followed by a positive IgG value within a very few days. This incubation period and timing for positive IgM and negative IgG at the time of hospitalization confirmed an acute HEV. Workup ruled out other viral causes of transaminitis.

Similarly, the incubation period of *Plasmodium falciparum* malaria ranges from a week to a month, which can explain the delayed presentation after the return and peak of symptoms (confused mental status, fever, transaminitis) after approximately 3 weeks. The CSF PCR was positive for *Plasmodium falciparum*, which established a cerebral malaria diagnosis. There was no evidence of cerebral edema, mass effect, or midline shift on CT head. The fundoscopic examination was unremarkable. The response to artemunate was rapid with prompt resolution of parasitemia on the peripheral smear. The only limitation in this study was the inability to repeat hepatitis E IgG analysis on outpatient blood testing as it would have left no stone unturned in confirming the diagnosis of acute HEV based on the projected timeline. Unfortunately, we were limited in our testing by financial constraints of the patient.

The two infections (HEV and malaria) have different vectors and different mechanisms of causing harm to human hosts. HEV spreads through the fecal-oral route. The female *Anopheles* mosquito transmits *Plasmodium* into human blood, which reaches the liver, undergoes asexual reproduction, and completes development prior to infecting red blood cells and multiplying [14]. The consequent disease manifestations are the result of microvascular occlusions and inflammatory responses generated by infected and ruptured erythrocytes.

The initial clinical presentation of altered mental status can be very misleading for the physician and unfortunate for the patient. Fever, thrombocytopenia, and abnormal liver enzymes paint a clinical picture remarkably familiar to COVID-19 in the current circumstances heightened by recent travel [15]. Delay in diagnosis and treatment of cerebral malaria is undisputedly terminal. Cerebral malaria has been misdiagnosed as psychosis and human rabies in the past [16]. Likewise, the absence of pharmacological prophylaxis or incorrect dosage puts a person at exceedingly high risk of cerebral malaria and its mortality [17–19].

While reviewing the literature, a study done in Afghanistan demonstrated a high incidence of hepatitis A and E and malaria due to a lack of health resources and sanitation measures [20]. Barcus et al. studied the association of hepatitis B and malaria in an endemic population in Vietnam, showing a higher tendency of patients in subgroups with cerebral malaria to test positive for HbsAg [21].

![Fig. 1 CT head without any evidence of intracranial changes, cerebral edema, mass effect, or midline changes](image-url)
Furthermore, co-infection with HEV and malaria has been reported with fatal consequences [22, 23]. So far, this is one of the first cases of co-infection where a patient’s malaria had advanced to cerebral malaria and the patient still had a favorable outcome. According to a WHO report (2018), malaria’s mortality rate is remarkably higher in females and younger children. This population is at higher risk of morbidity and mortality from HEV as well. The immune response is diminished with severe malarial infection, which can predispose patients to greater damage from HEV.

Potential synergistic hepatotoxicity was suggested by Nasir et al. when they studied hepatitis C and malaria co-infection [19]. Analogous co-infection in a person with underlying hepatic insufficiency or a pregnant woman can indeed be fatal and should be kept in mind. HEV causes viral cytotoxicity, while Plasmodium malaria affects the hepatic microvasculature by endothelial injury from the parasitized erythrocytes. A case of sporadic HEV in a patient with a history of malaria has been reported in the USA before, and physicians should be reminded of this association in relevant clinical settings even in first world countries [24]. Clinicians can avoid many neurological side effects if cerebral malaria is diagnosed in a timely manner and treatment is initiated [25, 26].

Conclusion

Malaria and viral hepatitis are indeed not the first thought in a physician’s mind when a patient comes in with vague complaints in an emergency room in a first world country. Particularly in the current circumstances, the threat of COVID-19 infection is real and is one of the top differential diagnoses in travelers. The liver enzyme levels in these patients are usually elevated, and suspicious personnel is managed conservatively with quarantine even if they test negative for COVID-19. COVID-19 should not hinder the thought process from ruling out other infectious etiologies. The suspicion of malaria and hepatitis should be high in patients with a recent travel history to endemic areas, particularly South Africa and South Asia. There is an exceedingly high mortality rate for malaria, particularly cerebral malaria, and efforts should be made to achieve prompt diagnosis and treatment. A detailed history should be taken from all available sources, and relevant blood testing should be ordered. Transaminitis and hyperbilirubinemia should raise the suspicion of potential endemic infections, such as malaria and viral hepatitis [27]. We propose that transaminitis should always trigger testing for peripheral blood smears and an acute hepatitis panel in sick returning travelers. Physicians should be aware of unconventional presentations with co-infection from common pathogens to avoid a delay in diagnosis. The already burdened health care systems cannot afford missed diagnoses of co-infections. A delay in a similar case of cerebral malaria and acute viral hepatitis can lead to fulminant hepatic necrosis with possibly fatal consequences. Lastly, timely detection and treatment saved this lucky patient from any neurological deficits, which is always a potential complication of cerebral malaria as discussed above. These patients should be closely monitored as outpatients after discharge. Travelers should utilize anti-malarial prophylactic medications and precautionary measures, including the use of long-sleeve clothing, mosquito repellents, and mosquito nets. Hepatitis A and E viruses mainly spread through the fecal-oral route. Clinicians should offer hepatitis (A, B, E) vaccinations to the patients and their close contacts to prevent illness in future infection events.

Abbreviations

E.R.: Emergency room; IV: Intravenous; ARDS: Acute respiratory distress syndrome; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; CDC: Centers for Disease Control and Prevention; CSF: Cerebrospinal fluid; GCS: Glasgow coma scale; PCR: Polymerase chain reaction.

Acknowledgments

Maria A. Farberov, MPA (Director, Clinical Research Programs SIUH), is acknowledged for ethical review for patient data use.

Authors’ contributions

Manuscript written and data obtained by SS, A.J (1), and A.J (2). Proofreading and literature review done by A.G, NM, and QI. All authors read and approved the final manuscript.

Funding

No funding was obtained from any organization or personnel during any stage of manuscript writing or submission.

Availability of data and materials

Patient-specific data were obtained from hospital electronic medical records of Northwell Health, and patient identifying information was cropped.

Declarations

Ethics approval and consent to participate

We reviewed the case report and manuscript with Research Department and Ethics Committee. No experimental intervention was performed, and it did not require any specification of guidelines, legislations, or permissions.

Consent for publication

The patient was contacted during the hospital stay and after discharge. Consent was obtained for the use of patient data, images, CSF studies, and blood work for the publication of the case for purely educational and research purposes, to which the patient and family agreed. No identifying information usage was explained.

Competing interests

No competing financial or personal interests are involved for all the authors.

Author details

1 Staten Island University Hospital, Staten Island, NY 10305, USA. 2 King Edward Medical University, Lahore 54000, Pakistan. 3 Department of Internal Medicine, Hofstra School of Medicine, Staten Island University Hospital, 475 Seaview Avenue, Staten Island, NY 10305, USA.
1. Idro R, Marsh K, John CC, Newton CR. Cerebral malaria: mechanisms of brain injury and strategies for improved neurocognitive outcome. Pediatr Res. 2010;68:267–74. https://doi.org/10.1203/PDR.0b013e3181ee738.

2. Nishanth G, Schlüter D. Blood-brain barrier in cerebral malaria: pathogenesis and therapeutic intervention. Trends Parasitol. 2019;35:516–28. https://doi.org/10.1016/j.pt.2019.04.010.

3. Siddiqui AJ, Adnan M, Jahan S, Redman W, Saeed M, Patel M. Neurological disorder and psychosocial aspects of cerebral malaria: what is new on its pathogenesis and complications? A minireview. Folia Parasitol (Praha). 2020. https://doi.org/10.14411/fp.2020.015.

4. Seydel RB, Kampondeni SD, Vailc M, Potchen MJ, Milner DA, Muvwalo FW, et al. Brain swelling and death in children with cerebral malaria. NEJM. 2015;372:1126–37. https://doi.org/10.1056/NEJMoa1401116.

5. Carter JA, Lees JA, Gona JK, Murira G, Rimba K, Neville BGR, et al. Severe *Plasmodium falciparum* malaria and acquired childhood language disorder. DM CN. 2006;48:51–7.

6. Boivin MJ, Bangirana P, Byarugaba J, Opoka RO, Idro R, Jurek AM, et al. Severe malaria: update on pathophysiology and treatment. Curr Opin Infect Dis. 2019;32:413–8. https://doi.org/10.1097/COQ.0000000000000584.

7. Amany G, Kizito S, Nabukenya I, Kalango J, Atuheire C, Nansumba H, et al. Risk factors, person, place and time characteristics associated with *Hepatitis E* virus outbreak in Napak district Uganda. BMC Infect Dis. 2017;17:451. https://doi.org/10.1186/s12879-017-2542-2.

8. Sévédé D, Doumbia M, Kouakou V, Djeihiffe V, Píneau P, Dosso M. Increased liver injury in patients with chronic hepatitis and IgG directed against hepatitis E virus. Esci j. 2019;18:955–61. https://doi.org/10.17179/esci.2019-1827.

9. Bagulo H, Majekodunmi AO, Welburn SC. Hepatitis E in Sub -saharan Africa: a significant emerging disease. One Health. 2021;11:100186. https://doi.org/10.1016/j. onehlt.2020.100186.

10. Riggle BA, Miller LH, Pierce SK. Desperately seeking therapies for cerebral malaria. J Immunol. 2020;204:327–34. https://doi.org/10.4049/jimmunol.1900829.

11. Kra O, Ouattara B, Aha T, Kadjané NJ, Kadjo K, Bissagnéné E, et al. Morbidity and mortality from infectious diseases at the military hospital of Abidjan, Côte d’Ivoire. Med Sante Trop. 2012;22:75–8. https://doi.org/10.1684/mtst.2012.0043.

12. Chrestensen SS, Edlick GD. Cerebral malaria as a risk factor for the development of epilepsy and other long-term neurological conditions: a meta-analysis. Trans R Soc Trop Med Hyg. 2015;109:233–8. https://doi.org/10.1093/trstmh/trv005.

13. Medica DL, Sinis P. Quantitative dynamics of *Plasmodium yoelii* sporozoite transmission by infected anopheline mosquitoes. Infect Immun. 2005;73:4363–9. https://doi.org/10.1128/iai.73.7.4363-4369.2005.

14. Pascarella G, Strumia A, Piliego C, Bruno F, Del Buono R, Costa F, et al. COVID-19 diagnosis and management: a comprehensive review. J Intern Med. 2020;288:192–206. https://doi.org/10.1111/joim.13091.

15. Mudyinanselage MH, Weerasinghe NP, Pathirana K, Dias H. Misdiagnosis of cerebral malaria initially as acute psychotic disorder and later as human rabies: a case report. BMC Res Notes. 2016;9:400. https://doi.org/10.1186/s13104-016-2211-3.

16. Pielok K, Kludkowska M, Zmyslowska S, Stefaniak J. Cerebral malaria and multi-organ dysfunction in an adult woman with *Plasmodium falciparum* infection imported from Cameroon: a case report. Ann Parasitol. 2019;65:427–31. https://doi.org/10.17420/ap6504.231.

17. Yapo Ette H, Koffi K, Botti K, Jouvet A, Effi AB, Honde M. Sudden death caused by parasites: postmortem cerebral malaria discoveries in the African endemic zone. Am J Forensic Med Pathol. 2002;23:202–7. https://doi.org/10.1016/S0196-9582(02)00019-9.

18. Nasir IA, Yakubu S, Mustapha JO. Epidemiology and synergistic hepatopathy of malaria and hepatitis C virus coinfection. Virology (Auckl). 2017. https://doi.org/10.1177/178122x17724411.

19. Carmo T, Safiullah S, Nicander E. Risk of enterically transmitted hepatitis A, hepatitis E, and *Plasmodium falciparum* malaria in Afghanistan. Clin Infect Dis. 2009;48:1800. https://doi.org/10.1086/599231.

20. Aslam S. Case study an interesting case of complicated *falciparum* malaria And hepatitis E virus co-infection. UCCJ. 2015;6:35–7.

21. Ghoshal U, Somani S, Chettri K, Akhtar P, Aggarwal R, Naik S. *Plasmodium falciparum* and hepatitis E virus co-infection in familial hepatic failure. JG. 2001;20:111.

22. Chandnani M, Kaur M, Ramadhas A, Tumarinson T. A case report about cerebral malaria initially as acute psychotic disorder and later as human rabies: a case report. JCEH. 2014.05.007.